DXCM DEXCOM INC.

Dexcom Looks to the Future of Continuous Glucose Monitoring

(Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the publication and presentation of two new studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).

Focused on clinical outcomes of CGM use in broader and more diverse populations and new data from Dexcom’s next-generation G7 CGM, these two studies mark a pivotal moment in diabetes care innovation at one of the world’s leading industry conferences.

MOBILE Study

The , published in the Journal of the American Medical Association, is the first of its kind to find that people with Type 2 diabetes who use basal, or background, insulin, benefited from the use of CGM. With the publication of the MOBILE data, Dexcom has now demonstrated significant outcomes driven by its CGM technology in randomized controlled trials across the full spectrum of insulin use in people with diabetes.

Key clinical benefits of Dexcom CGM use in this population included:

  • Increased time in range
  • Significant A1c reduction
  • More patients reaching A1c goals
  • A profound decrease in hyperglycemia

The randomized clinical trial led by HealthPartners Institute’s International Diabetes Center and coordinated by The Jaeb Center for Health Research in Tampa, Fla. affirms Dexcom’s belief in the power of CGM for all people with diabetes regardless of Type.

“The clinical benefits of Dexcom CGM were seen across all patient demographics regardless of age, education, numeracy or socioeconomic status,” said David Price, MD, vice president of medical affairs at Dexcom. “The MOBILE study design also affirms our ability to meet the needs of the diverse communities we serve.”

MOBILE Study Findings

  • The group of patients using Dexcom CGM spent an average of 3.8 hours more each day within the optimal range of blood glucose levels (70-180 mg/dL), 3.6 hours less each day in the very high glucose range (>250 mg/dL), and with a reduction in CGM measured hypoglycemia in the CGM group compared to the finger-stick glucose monitoring group
  • 63% of patients using CGM to guide therapy adjustments had an HbA1c less than 8% compared to only 39% of patients using finger-stick glucose reading
  • The group using CGM to guide therapy and lifestyle adjustments also had significantly lower HbA1c levels (9.1 to 8.0%) than the group of patients using traditional finger-stick glucose monitoring (9.0 to 8.4%); this was an adjusted difference in mean change in HbA1c of −0.4%, 95% CI –0.8% to −0.1%, P=0.02
  • Adherence and satisfaction were also high among the CGM group

MOBILE Study Design

  • Eight-month study of 175 ethnically and socioeconomically diverse adults (including >50% people of color) across 15 clinical sites
  • Type 2 diabetes age 30 years or older who were receiving diabetes care from a primary care provider trying to manage their diabetes using basal or background insulin, but not using faster-acting insulin at meals
  • Two-thirds of the trial participants were assigned to use Dexcom CGM and encouraged to use Dexcom’s CLARITY, Share and Follow software applications; the remaining one third of the trial patients were assigned to use the traditional blood glucose meter

Dexcom G7 Data

Dexcom also presented new data on its next generation interoperable CGM, Dexcom G7, drawn from clinical trials supporting the company’s efforts toward a CE Mark submission and US pre-pivotal work. The data represents the latest G7 technology, demonstrating the consistent performance of the sensor across the spectrum of glucose readings and duration of wear.

G7 Results (approximately 360 sensor sessions)

  • An overall mean absolute relative difference (MARD) of 8.7%
  • 93.8 percent %20/20
  • 99% of sensor readings were clinically accurate and safe for treatment decisions

Expected Dexcom G7 Features and Benefits

  • 60% smaller wearable than G6
  • Smaller all-in-one sensor applicator and transmitter
  • 30-minute warm-up
  • Interoperability with insulin delivery devices
  • Maintaining world class customer experience
  • Continued best-in-class accuracy

“Initial clinical data has only strengthened our conviction that Dexcom G7 will build upon the high accuracy standard already established by our G6 CGM system,” said Jake Leach, executive vice president and chief technology officer at Dexcom. “The G7 is a completely redesigned CGM; our users will get a whole suite of new features that we believe will enhance the customer experience that has become synonymous with Dexcom.”

In addition to the MOBILE study and G7 data, many other presentations and posters from ATTD reinforced the benefits of Dexcom CGM for intensive insulin management, as well as its use in inpatient settings and during pregnancy.

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked DexCom highest in customer satisfaction and loyalty. For more information, visit .

EN
03/06/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DEXCOM INC.

Dexcom Inc: 1 director

A director at Dexcom Inc sold/sold after exercising options 4,137 shares at 140.000USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...

 PRESS RELEASE

Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-t...

SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription. There are approximately 25 million people in the U.S. living with Type 2 diabetes who do not use insulin and who can benefit from continuous glucose monitoring (CGM) technology. Today, Dexcom G7 is available for them with a prescription. Stelo, cleared for use without a prescription, will make it even easier for this population to access lead...

 PRESS RELEASE

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 D...

EDINBURGH, Scotland--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced compelling new clinical evidence supporting the use of Dexcom continuous glucose monitoring (CGM) for automated insulin delivery (AID) systems. Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes. The evidence and d...

 PRESS RELEASE

Dexcom Announces Upcoming Conference Presentation

SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5th. The live presentation is scheduled to begin at approximately 8:40 AM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. DexCom, Inc. empowers people to take real-time control of health through ...

 PRESS RELEASE

Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results

SAN DIEGO--(BUSINESS WIRE)-- (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: Revenue grew 27% versus the same quarter of the prior year to $1.03 billion on a reported basis and 26% on an organic1 basis. U.S. revenue growth of 27% and international revenue growth of 27% on a reported basis. International revenue growth was 23% on an organic1 basis. GAAP operating income of $216.9 million or 21.0% of revenue, an increase of 560 basis points compared to the fourth quarter o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch